RNA's Rousing New Adventure

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Dicerna is a case in point: RNA-based and related medicines — mRNA, RNAi, CRISPR, gene and cell therapies — are now receiving new attention and support after years of struggle and setbacks.

The change is largely due to many companies doing extensive work to solve the associated problems and improve the technologies behind such products. But, more recently, the COVID-19 pandemic and mRNA vaccines developed to fight it have generated a fresh wave of acceptance for RNA- and gene-based therapies.